Navigation Links
Shire Continues to Deliver Excellent Growth From Core Products
Date:10/30/2009

come for the three months to September 30, 2009 is lower than the same period in 2008 due to significantly lower interest rates in 2009 compared to 2008, and lower average cash and cash equivalent balances.

    Interest expense
                                                              2009     2008
                                                                $M       $M

    Interest expense (US GAAP)                                 9.4     92.9
    Additional interest on settlement of appraisal rights
    litigation                                                   -    (73.0)
    Interest expense (Non GAAP)                                9.4     19.9

For the three months to September 30, 2009 the Company incurred interest expense of $9.4 million (2008: $92.9 million). Interest expense in 2008 was higher than 2009 due to accrued interest expense of $77.0 million recorded in respect of the Transkaryotic Therapies, Inc. ("TKT") appraisal rights litigation; of the $77.0 million, $73.0 million was additional interest arising from the settlement of the litigation in November 2008.

    Other income/(expense), net
                                                               2009     2008
                                                                 $M       $M

    Other income/(expense), net (US GAAP)                       7.0    (52.0)
    Other than temporary impairment of available for sale         -     54.1
    securities
    Other income, net (Non GAAP)                                7.0      2.1

Non GAAP other income, net in 2009 was higher than the same period in 2008 due to a gain recognized following the substantial modification of a property lease.

Taxation

The effective rate of tax for the three months to September 30, 2009 was 34% (2008: -103%), and the effective tax rate on Non GAAP income is 33% (2008: 19%).

The Non GAAP effective tax r
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014 Levi & Korsinsky ... in the United States District Court for the District ... investors who purchased Galectin Therapeutics Inc. ("Galectin" or the ... July 28, 2014. For more information, click ... that during the Class Period the Company violated federal ...
(Date:8/28/2014)... , August 28, 2014 ... "DNA diagnostics Market (products, applications, techniques, end users ... Growth and Forecast, 2013 - 2020," indicates that ... billion by 2020 registering a CAGR of 9.8% ... accurate diagnosis and cost effectiveness over alternative diagnostic ...
(Date:8/28/2014)... /PRNewswire-iReach/ -- Gateway Analytical announced today that they ... Annual Global Pharma Manufacturing Summit in ... The Global Pharma Manufacturing Summit offers a networking ... biologic pharmaceutical manufacturing. The conference is focused on ... such as the increasing pressure to grow and ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 3Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3
... May 6, 2011 CryoLife, Inc. (NYSE: ... tissue processing company, today announced the final results of ... owned subsidiary CL Falcon, Inc., for 49.9 percent of ...  The tender offer expired at 12:00 midnight, Eastern Time, ...
... Ferring Pharmaceuticals Inc., the makers of FIRMAGON® (degarelix for injection), ... the race to end prostate cancer as an official sponsor ... growing men,s health event series in the United States. Now ... (GPCC) is led by ZERO – The Project to ...
Cached Medicine Technology:CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 2CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 3CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 4CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 5CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 6Ferring Pharmaceuticals to Support Great Prostate Cancer Challenge® Events Across the Country in National Effort to End Prostate Cancer 2Ferring Pharmaceuticals to Support Great Prostate Cancer Challenge® Events Across the Country in National Effort to End Prostate Cancer 3
(Date:8/28/2014)... did the earliest birds take wing? Did they fall from ... Or did they run along the ground and pump their ... million years in the past, but a new University of ... birds have an innate ability to maneuver in midair, a ... rather than fall from a perch. , The study looked ...
(Date:8/28/2014)... NJ Top Docs Presents Dr. Christophe Oliveira ... Top Doc, Dr. Christophe Oliveira, has just announced ... for the department of transportation. Dr. Oliveira has ... all drug testing for commercial drivers. , Having ... disorders including disk herniations, spinal stenosis, muscle sprains/strains, ...
(Date:8/28/2014)... (BRONX, NY) Researchers from Albert Einstein College of ... a potential antibody therapy for Sudan ebolavirus (SUDV), one of ... the Zaire ebolavirus (EBOV), is now devastating West Africa. First ... (most recently in 2012) that have killed more than ... ACS Chemical Biology . , Between 30 and 90 ...
(Date:8/28/2014)... In 2012, The Ben & Catherine Ivy Foundation ... brain cancer research projects at the Translational Genomics ... officially received the final regulatory approval from University ... for the trial can begin. , In the ... Trial," TGen and its clinical partners will lead ...
(Date:8/28/2014)... A herbal preparation prescribed by a Chinese herbal ... in life-threatening heart changes, prompting a team of ... appropriate patient education by practitioners who prescribe complementary ... , the journal of the Australasian College for ... and Dr Nicky Dobos from the Intensive Care ...
Breaking Medicine News(10 mins):Health News:Flapping baby birds give clues to origin of flight 2Health News:Flapping baby birds give clues to origin of flight 3Health News:NJ Top Docs Presents Dr. Christophe Oliveira of Rehabilitation Instiute of North Jersey 2Health News:NJ Top Docs Presents Dr. Christophe Oliveira of Rehabilitation Instiute of North Jersey 3Health News:Drug shows promise against Sudan strain of Ebola in mice 2Health News:TGen receives approval for patient enrollment in brain cancer clinical trial 2Health News:Deadly remedy: Warning issued about Chinese herbal medicine 2
... Bulgaria’s Agriculture Minister Nihat Kabil has revealed that ... bird flu. The bird was however not infected ... dangerous H5 virus. The dead swan was found ... was unable to say whether avian flu had ...
... expected in poultry during the course of 2006, according to ... take place // among human beings on a large scale, ... Governments have however been called upon to be prepared ... have been called upon to improve their surveillance where the ...
... end up losing as many as over 200 doctors, over the ... abortion. // The Catholic doctors who are from Queensland are of ... be deprived of his powers when it comes to deciding upon ... ,The AMA on the other hand is calling for ...
... meeting with Boston Scientific to talk about the repairs in ... held in 2001 with Schering-Plough // about problems with its ... to make any amendments. This provoked the FDA to withhold ... solve this problem Raul E. Cesan, the company's president and ...
... of the Teratology Society published a paper in the journal ... ,In this paper they said that overweight and ... develop medical problems at birth. ,This paper talked ... obese mothers. , It is stated that they ...
... closely monitored surveillance for patients with colon and rectal ... recurrence // compared to less aggressive strategy which is ... found that an intensified follow up of patients in ... diagnosis of cancer recurrence which could help in treatment ...
Cached Medicine News:
... The Devex Mesh System is indicated for ... a diseased vertebral body resected or excised for ... of the spinal cord and neural tissues, and ... body. Devex Mesh System is also indicated for ...
... Ocelot stackable cage system provides anterior column ... total vertebrectomies from T1 to L5. The ... Carbon fiber polymer cages that are stacked ... needs. The Peek Carbon fiber reinforced polymer ...
... Vitoss engineered to resemble ... and structure. -TCP constructs ... in spinal arthrodesis surgery ... due to trauma and ...
... system provides anterior column support for single ... T1 to L5. The system consists of ... cages that are stacked to a desired ... Carbon fiber reinforced polymer material emulates the ...
Medicine Products: